Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.21

€8.21

4.530%
0.356
4.530%
€25.09
 
03.07.25 / Frankfurt WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

EyePoint Pharmaceuticals Inc. Stock

EyePoint Pharmaceuticals Inc. dominated the market today, gaining €0.36 (4.530%).
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 25 € there is potential for a 204.51% increase which would mean more than doubling the current price of 8.21 € for EyePoint Pharmaceuticals Inc..
So far the community has only identified positive things for EyePoint Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of EyePoint Pharmaceuticals Inc. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of EyePoint Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
EyePoint Pharmaceuticals Inc. 4.530% -4.867% 18.028% 4.003% 22.941% 11.701% 29.291%
Krystal Biotech 0.370% 2.066% 4.579% -26.369% -20.466% 95.242% -
Ardelyx Inc. -1.560% 15.019% 12.419% -25.797% -26.888% 538.073% -41.452%
Evolus Inc -0.660% -1.948% -11.176% -22.959% -28.095% -30.734% 59.283%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-10-31

Betrachtet man zunächst die allgemeinen Finanzen von EyePoint Pharma (EYPT), einem Unternehmen aus der Branche für Biotechnologie und medizinische Forschung, lassen sich einige Schlüsseltrends erkennen. Mit einer Marktkapitalisierung von 185 Millionen US-Dollar rangiert das Unternehmen im mittleren Segment des Markts. Dies deutet darauf hin, dass es trotz der Tatsache, dass es in einer Branche tätig ist, die bekanntermaßen hohe Entwicklungskosten hat, eine bemerkenswerte finanzielle Stabilität aufweist.

Der erste Eindruck, der sich aus diesen Zahlen ergibt, ist jedoch keineswegs überwältigend positiv. Einen erheblichen Einfluss darauf hat der deutlich negative Betriebsgewinn (EBITDA) von -84 Millionen US-Dollar sowie weitere wichtige Kennzahlen wie die Profitmarge und die operative Marge, die beide ebenfalls im negativen Bereich liegen.

Wie bei jeder Bewertung eines Unternehmens gilt es, die positiven Aspekte gegen die negativen abzuwägen. Bei EyePoint Pharma ist eines der hervorstechenden positiven Elemente der Buchwert von 1,67 USD. Dies kann ein Indikator dafür sein, dass das Unternehmen über bedeutende Vermögenswerte verfügt - ein potenzielles Sicherheitsnetz, falls es Schwierigkeiten begegnen sollte.

Comments

Prediction Buy
Perf. (%) -0.34%
Target price 24.237
Change
Ends at 17.06.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 30.69%
Target price 19.551
Change
Ends at 29.05.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 48.34%
Target price 23.210
Change
Ends at 16.05.26

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Mizuho from $30.00 to $26.00. They now have an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat
Show more